Gene Mutations as a Target in Metastatic Prostate Cancer

The incidence of germline mutations in DNA-repair genes was significantly higher in men with metastatic versus localized disease.

The recent report of a high response to PARP1 inhibitors among heavily treated metastatic castration-resistant prostate cancer patients with DNA-repair defects (NEJM JW Oncol Hematol Dec 2015 and N Engl J Med 2015; 373:1697) has led to additional efforts to more fully characterize the potential role of germline DNA-repair mutations, which, although limited in unselected patients with localized prostate cancer, is undefined in advanced disease.

To analyze DNA-repair genes associated with autosomal-dominant cancer-predisposition syndromes, investigators added 542 men from six different international cohorts to a previous reported series of 150 men with metastatic prostate cancer (Cell 2015; 161:1215). Patients were unselected regarding family …

Reviewing Author

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, FACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Gene Mutations as a Target in Metastatic Prostate Cancer

Topics

Reviewing Author